Key Takeaways Regulatory approvals in the U.S. for liver and heart technologies and Canadian market expansions may significantly boost revenue and market share in North America. Strategic improvements in the Abdominal segment are set to increase gross margins and profitability, while strong adoption in Australia indicates promising growth.Read more
Key Takeaways Growth prospects are supported by demographic trends and product advantages but challenged by hospital cost constraints, regulatory delays, and slower market adoption than expected. Margin and earnings growth face headwinds from rising competition, ambitious expansion investments, and operational obstacles in scaling recurring service revenues.Read more
Key Takeaways Unmet demand and rapid account activation are driving faster recurring revenue and margin expansion, positioning Xvivo for structural profitability improvement ahead of expectations. Broadening customer adoption and digital innovation are establishing strong competitive advantages, enabling Xvivo to capture market share amid global transplant growth and unlock new revenue streams.Read more
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
